Innovative Platform NanoView Biosciences has developed the ExoView platform, a next-generation solution for sensitive detection and characterization of extracellular vesicles, including exosomes and viruses. This advanced technology can be targeted toward research institutions and biotech companies focused on extracellular vesicle analysis and biomarker discovery.

Recent Acquisition Following its acquisition by Unchained Labs in 2022, NanoView benefits from increased resources and potential integration into a broader portfolio of life science tools, creating cross-selling opportunities in research and clinical markets seeking comprehensive exosome and EV analysis solutions.

Research Collaborations Active partnerships, such as the collaboration with Beth Israel Deaconess Medical Center, highlight NanoView’s focus on applied research in cancer and immunotherapy. These partnerships open doors for clinical and pharma customers looking to leverage exosome biomarkers for diagnostics and personalized medicine.

Growing Market Relevance With the increasing interest in extracellular vesicles and exosomes for diagnostics and therapeutics, NanoView’s focus on innovative, high-throughput analysis platforms positions it well to tap into expanding markets driven by cellular communication and biomarker research.

Funding and Development With $10 million in funding and a small team of up to 50 employees, NanoView is positioned for targeted sales outreach to biotech and academic research institutions that require cost-effective, scalable solutions for exosome analysis, supporting expansion into clinical and commercial applications.